ADC Series (V)ADC Resistance: Why Do Antibody–Drug Conjugates Lose Effectiveness?
- Jason Lu
- Feb 22
- 3 min read
Article Positioning
This is Series (V) in the ADC deep-dive.
In previous articles, we explored:
This article focuses on a critical reality:
Even clinically successful ADCs eventually face ADC resistance.
Understanding the mechanisms of ADC resistance is essential not only for biology, but for long-term product strategy.
Executive Summary
ADC resistance is multifactorial and biologically inevitable.
Antigen downregulation and tumor heterogeneity reduce drug delivery.
Altered internalization and lysosomal trafficking limit intracellular payload release.
Lysosomal dysfunction may impair payload activation.
ABC transporters can export cytotoxic payloads.
DNA damage response and apoptotic threshold shifts reduce drug lethality.
Next-generation ADC strategies aim to delay, diversify, and manage resistance rather than eliminate it.
1. Antigen Downregulation and Tumor Heterogeneity
One of the most intuitive forms of ADC resistance is reduced target expression.
Tumor cells may:
Downregulate antigen expression
Acquire mutations
Exhibit heterogeneous antigen density
Because ADC efficacy is partially quantitative, reduced antigen density lowers intracellular payload accumulation.
Tumor heterogeneity further enables resistant subclones to survive selective pressure.
2. Altered Internalization and Trafficking
Even when antigen expression remains stable, resistance can arise from:
Slower receptor-mediated endocytosis
Increased receptor recycling
Reduced lysosomal trafficking efficiency
Since many ADCs rely on lysosomal degradation to release active payloads, altered intracellular trafficking directly contributes to ADC resistance.
3. Lysosomal Dysfunction and Payload Release Failure
Effective payload liberation often depends on:
Lysosomal acidification
Protease activity
Proper intracellular catabolism
Changes in lysosomal function may impair:
Antibody degradation
Linker cleavage
Activation of the cytotoxic drug
In this scenario, ADC internalization occurs, but payload activation becomes inefficient.
4. Drug Efflux Mechanisms
Certain payload classes may act as substrates for ABC transporters such as MDR1 (P-glycoprotein).
Upregulation of efflux pumps reduces intracellular drug retention and exposure time.
This represents a payload-specific mechanism of ADC resistance.
5. DNA Damage Response and Downstream Adaptation
For DNA-damaging payloads, such as topoisomerase I inhibitors, tumor cells may adapt through:
Upregulation of DNA repair pathways
Cell cycle checkpoint modulation
Increased apoptotic threshold
These adaptations reduce cytotoxic impact despite adequate drug delivery.
This category represents downstream resistance beyond drug transport.
6. Tumor Microenvironment Constraints
In solid tumors, resistance may also be influenced by:
Limited tissue penetration
Elevated interstitial pressure
Spatial barriers
These factors reduce effective tumor exposure and allow partially protected subpopulations to persist.
7. Next-Generation Strategies to Address ADC Resistance
Rather than attempting to eliminate resistance entirely, newer strategies focus on delaying and diversifying tumor adaptation.
Dual-Payload ADCs
Delivering two mechanistically distinct payloads may reduce reliance on a single cytotoxic pathway.
Multispecific ADCs
Targeting multiple antigens may mitigate the impact of single-target downregulation.
Novel Payload Classes
Designing payloads with reduced efflux susceptibility or alternative mechanisms broadens therapeutic options.
Immune-Modulating ADCs (Emerging Field)
Early-stage strategies aim to combine cytotoxic and immune activation effects.
From Mechanism to Lifecycle Strategy | LuTra Studio Consulting
Understanding ADC resistance is not only a mechanistic challenge — it is a lifecycle management issue.
Early-stage decisions about:
Target durability
Internalization behavior
Payload class selection
Platform extensibility
directly influence long-term resistance trajectories.
At LuTra Studio, we support teams in integrating biological insight with engineering feasibility and long-term strategic positioning.
A resilient ADC program is defined not by initial response rates, but by how well it anticipates tumor evolution.
Closing Perspective
ADC resistance does not indicate failure of the technology.
It defines its biological boundaries.
The goal of next-generation ADC development is not to eliminate resistance entirely, but to design systems that remain effective within evolving tumor ecosystems.
References
Loganzo, F., Sung, M., & Gerber, H.-P.
Mechanisms of Resistance to Antibody–Drug Conjugates.
Molecular Cancer Therapeutics, 2016; 15(12):2825–2834.
https://aacrjournals.org/mct/article/15/12/2825/147824/Mechanisms-of-Resistance-to-Antibody-Drug
Shoaib, A. M., et al.
Resistance mechanisms to antibody–drug conjugates in cancer therapy and strategies to overcome them.
Cancer Drug Resistance, 2025; 8:148.
Eltaib, L., Afzal, M., Maji, C., et al.
Mechanisms of resistance to antibody–drug conjugates in cancer: molecular barriers and pharmacological solutions.
Cancer Chemotherapy and Pharmacology, 2025; 95:118.
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N.
Strategies and challenges for the next generation of antibody–drug conjugates.
Nature Reviews Drug Discovery, 2017; 16:315–337.
Drago, J. Z., Modi, S., & Chandarlapaty, S.
Unlocking the potential of antibody–drug conjugates for cancer therapy.
Nature Reviews Clinical Oncology, 2021; 18:327–344.
Robey, R. W., Pluchino, K. M., Hall, M. D., et al.
Revisiting the role of ABC transporters in multidrug-resistant cancer.
Nature Reviews Cancer, 2018; 18:452–464.
Casi, G., & Neri, D.
Antibody–drug conjugates: Basic concepts, examples and future perspectives.
Journal of Controlled Release, 2012; 161(2):422–428.
https://www.sciencedirect.com/science/article/abs/pii/S0168365912000314
Comments